Headquartered in Vancouver, WA Fiscal year ends December NASDAQ: ABSI absci.com
Absci Corporation is a clinical-stage biopharmaceutical company that combines generative AI with synthetic biology to design and develop novel antibody-based therapeutics. The company's Integrated Drug Creation platform uses a continuous feedback loop between advanced AI algorithms and wet lab validation to rapidly design innovative biologics targeting challenging therapeutic targets. Absci's lead asset, ABS-201, is an AI-designed anti-prolactin receptor antibody currently in Phase 1/2a clinical trials for pattern hair loss (androgenetic alopecia), with planned expansion into endometriosis. The company also has a preclinical pipeline focused on metabolism and immunology & inflammation, including ABS-202 for an undisclosed I&I indication. Absci generates revenue through drug creation partnerships with major pharmaceutical and biotech companies, with more than 25 partnered programs to date. The company operates wet and dry laboratories in Vancouver, WA, AI research labs in New York City and Serbia, and an Innovation Center in Switzerland, employing approximately 140 people. Updated
AMD just filed its first-ever 13F, and buried inside a $1.31 billion portfolio are five positions that trace exactly where the company believes AI infrastructure spending lands next, including one ticker most…
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one…
Absci Corporation is a clinical-stage biopharmaceutical company that combines generative AI with synthetic biology to design and develop novel antibody-based therapeutics.
The Wall Street consensus 12-month price target for ABSI is $14.40.
